Protective and therapeutic effects of milrinone on acoustic trauma in rat cochlea
- 53 Downloads
The aim of this study was to investigate the potential protective and therapeutic effects of milrinone, a specific phosphodiesterase (PDE) III inhibitor, on acoustic trauma-induced cochlear injury and apoptosis.
A total number of 30 healthy Wistar albino rats were evenly divided into five groups as follows: group 1 was assigned as control group; group 2 and 3 were assigned as low-dosage groups (0.25 mg/kg) in which milrinone was administered 1 h before acoustic trauma (AT) and 2 h after AT, respectively; group 4 and 5 were assigned as high-dosage groups (0.50 mg/kg) in which the drug was administered 1 h before AT and 2 h after AT, respectively. Except control group, all treatment groups received a single dosage of milrinone for 5 days. Distortion product otoacoustic emissions (DPOAE) measurements were recorded before AT as well as at second and fifth post-traumatic days. At the end of fifth day, all rats were sacrificed and the cochlea of the rats was removed for histopathological evaluation. In addition, the groups were compared in terms of apoptotic index via caspase-3 staining.
In terms of signal-to-noise ratio (SNR), there was no statistically significant difference among the groups following AT (p > 0.05). After 5 days of milrinone treatment, the best SNR values were found in group 5, though all groups did not statistically differ (p > 0.05). In histopathological evaluation, vacuolization, inflammation, and edema scores in all treatment groups were statistically lower than those of the control group (p < 0.05). In group 2 and 4 where the drug was administered before AT, the inflammation and apoptosis index was lower than those of group 3 and 5 where the drug was administered after AT (p < 0.0001).
We reveal that milrinone has a protective effect on cochlear damage in the experimental acoustic model of rats. This protective effect was more apparent following the pre-traumatic milrinone administration, and is associated with its effect on decreasing inflammation and apoptosis. Based on DPOAE measurements following AT, especially in the group 5 (high-dosage group), milrinone may also have a therapeutic effect.
KeywordsMilrinone Acoustic trauma Hearing loss Caspase 3 Apoptosis Inner ear
Compliance with ethical standards
Conflict of interest
We have neither financial disclosure nor conflict of interest.
The study was performed in accordance with the 2011 Guide for the Care and Use of Laboratory Animals.
- 5.Fetoni AR, Ralli M, Sergi B, Parrilla C, Troiani D, Paludetti G (2009) Protective effects of N-acetylcysteine on noise-induced hearing loss in guinea pigs. Acta Otorhinolaryngol Ital 29:70Y5Google Scholar
- 7.Lorito G, Giordano P, Petruccelli J, Martini A, Hatzopoulos S (2008) Different strategies in treating noiseinduced hearing loss with N-acetylcysteine. Med Sci Monit 14(8):159–164Google Scholar
- 16.Uysal E, Dokur M, Altınay S, Saygılı Eİ, Batcıoglu K, Ceylan MS, Kazımoglu H, Uyumlu BA, Karadag M (2017) Investigation of the effect of milrinone on renal damage in an experimental non-heart beating donor model. J Investig Surg 14:1–10Google Scholar
- 25.Sendowski I (2006) Magnesium therapy in acoustic trauma. Magnes Res 19(4):244–254Google Scholar
- 41.Jafari A, Baghaei A, Solgi R, Baeeri M, Chamanara M, Hassani S, Gholami M, Ostad SN, Sharifzadeh M, Abdollahi M (2015) An electrocardiographic, molecular and biochemical approach to explore the cardioprotective effect of vasopressin and milrinone against phosphide toxicity in rats. Food Chem Toxicol 80:182–192CrossRefGoogle Scholar
- 42.Morrill S, He DZZ (2017) Apoptosis in inner ear sensory hair cells. J Otol 12:151e164Google Scholar
- 51.Lopes AC, Otowiz VG, de Barros Lopes PM, Lauris JRP, Santos CC (2012) Prevalence of noise-induced hearing loss in drivers. Int Arch Otorhinolaryngol 16:509–514Google Scholar
- 52.Desjardins S, Cauchy MJ (1989) Acute effects of milrinone on the electrocardiogram and the cardiac hemodynamics of rats with pressure overload-induced congestive heart failure. Arch Int Pharmacodyn Ther 301:182–199Google Scholar